Kadcyla Approval History

  • FDA approved: Yes (First approved February 22nd, 2013)
  • Brand name: Kadcyla
  • Generic name: ado-trastuzumab emtansine
  • Company: Genentech, Inc.
  • Treatment for: Breast Cancer

Kadcyla (ado-trastuzumab emtansine) is a HER2-targeted antibody and microtubule inhibitor conjugate indicated for the treatment of patients with HER2-positive, metastatic breast cancer.

FDA Approval History for Kadcyla

DateArticle
Feb 22, 2013Approval FDA Approves Kadcyla for Late-Stage Breast Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web5)